FDA Vaccine Chief Vinay Prasad Leaving Agency After Controversies

WASHINGTON — Dr. Vinay Prasad, the Food and Drug Administration’s vaccine chief, is departing the agency for a second time, a move announced late Friday by FDA Commissioner Marty Makary. Prasad will return to his academic position at the University of California, San Francisco, at the end of April. This latest departure follows a period of controversy surrounding decisions related to vaccine reviews and treatments for rare diseases, and comes less than a year after a previous, brief removal from his post.

Prasad’s initial departure in July 2025, and subsequent reinstatement, stemmed from disagreements over the agency’s approach to evaluating vaccines and specialty drugs. His return to the FDA was backed by Health Secretary Robert F. Kennedy Jr. And Commissioner Makary, but the underlying tensions appear to have persisted, culminating in this second exit. The timing of this announcement, and the context of ongoing disputes with pharmaceutical companies and regulators, raises questions about the direction of the FDA under the current administration.

Recent Disputes and FDA Scrutiny

In recent weeks, Prasad faced criticism for several decisions that challenged established FDA procedures. A particularly contentious issue involved the agency’s initial refusal to review a new mRNA flu vaccine developed by Moderna. This rejection, unusual for the FDA, prompted Moderna to publicly challenge the decision and demand a formal review. The FDA subsequently reversed course, agreeing to review the vaccine pending an additional study from the company. As reported by the Associated Press, this reversal highlighted the internal disagreements within the agency.

Further complicating matters, the FDA engaged in a public dispute with UniQure, a company developing a gene therapy for Huntington’s Disease. The FDA requested a new trial that would include a sham surgery control group, a demand UniQure executives argued contradicted previous agency guidance and raised ethical concerns for patients. The FDA defended its request at a press conference, calling the initial study results “stone cold negative.” This unusual public confrontation underscored the increasing friction between the agency and the companies it regulates.

A History of Controversy

Prasad’s tenure at the FDA has been marked by a pattern of challenging conventional approaches to drug and vaccine approvals. Since arriving at the agency in May 2025, he has overseen a series of rejections and requests for additional studies for therapies targeting rare and difficult-to-treat conditions. This approach has drawn criticism from pharmaceutical executives and investors, who argue that it adds unnecessary delays and costs to the drug development process. According to Politico, more than half a dozen drugmakers have received such requests, potentially delaying access to innovative treatments.

Prasad’s background as a longtime academic and critic of the FDA’s standards likely influenced his approach to regulation. While he and Commissioner Makary initially aimed to streamline the drug review process, Prasad also imposed new warnings and study requirements, particularly for COVID-19 vaccines – a focus aligned with Health Secretary Kennedy Jr.’s long-held skepticism towards vaccines.

Implications for FDA Regulation

Prasad’s departure raises questions about the future direction of the FDA and its relationship with the pharmaceutical industry. His willingness to challenge established norms and demand more rigorous evidence for drug approvals has been praised by some as a necessary step to ensure patient safety. However, others argue that his approach has created uncertainty and discouraged innovation. The ongoing disputes with companies like Moderna and UniQure suggest a growing tension between the FDA’s regulatory role and the industry’s desire for faster approvals.

The FDA’s handling of these cases also highlights the complexities of evaluating new therapies, particularly for rare diseases where traditional clinical trial designs may be difficult to implement. The request for a sham surgery control group in the UniQure trial, for example, sparked ethical concerns and raised questions about the feasibility of conducting such a study.

What Comes Next for the FDA

With Prasad’s departure, the FDA will need to navigate these challenges while maintaining public trust in its regulatory processes. The agency is currently reviewing several high-profile vaccine and drug applications, and its decisions will have significant implications for public health. The FDA will likely face continued scrutiny from both industry and advocacy groups as it seeks to balance the need for innovation with the imperative to ensure patient safety. The agency’s next steps will involve identifying a replacement for Prasad and clarifying its approach to evaluating new therapies, particularly those targeting rare diseases. The Washington Post reports that the agency has not yet announced a timeline for selecting a successor.

The situation also underscores the broader political context surrounding the FDA, with Health Secretary Kennedy Jr.’s influence likely to continue shaping the agency’s priorities. As the FDA moves forward, it will need to address the concerns raised by Prasad’s departure and work to rebuild trust with both the pharmaceutical industry and the public.